View ValuationHelyx Industries 将来の成長Future 基準チェック /06現在、 Helyx Industriesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Oct 17Price target increased by 18% to €1.16Up from €0.98, the current price target is an average from 2 analysts. New target price is 12% above last closing price of €1.04. Stock is up 8.7% over the past year. The company is forecast to post a net loss per share of €0.12 next year compared to a net loss per share of €0.24 last year.Breakeven Date Change • May 24No longer forecast to breakevenThe analyst covering Ulisse Biomed no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €269.2k in 2024. New forecast suggests the company will make a loss of €530.0k in 2025.Price Target Changed • Nov 16Price target decreased to €1.65Down from €2.15, the current price target is provided by 1 analyst. New target price is 53% above last closing price of €1.08. Stock is down 69% over the past year. The company posted a net loss per share of €0.075 last year.すべての更新を表示Recent updatesNew Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.9m free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Revenue is less than US$5m (€1.9m revenue, or US$2.2m). Market cap is less than US$100m (€15.8m market cap, or US$18.3m).Reported Earnings • Apr 16Full year 2025 earnings releasedFull year 2025 results: Revenue: €2.23m (up 191% from FY 2024). Net loss: €4.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in Europe.New Risk • Apr 15New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 61% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.3m net loss in 2 years). Revenue is less than US$5m (€926k revenue, or US$1.1m). Market cap is less than US$100m (€15.3m market cap, or US$18.0m).お知らせ • Apr 14Helyx Industries S.p.A., Annual General Meeting, Apr 28, 2026Helyx Industries S.p.A., Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: via montebello n 27, milano ItalyNew Risk • Mar 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€2.7m). Currently unprofitable and not forecast to become profitable over next 3 years (€3.0m net loss in 3 years). Share price has been volatile over the past 3 months (7.2% average weekly change). Revenue is less than US$5m (€926k revenue, or US$1.1m). Market cap is less than US$100m (€16.4m market cap, or US$18.9m).Price Target Changed • Oct 17Price target increased by 18% to €1.16Up from €0.98, the current price target is an average from 2 analysts. New target price is 12% above last closing price of €1.04. Stock is up 8.7% over the past year. The company is forecast to post a net loss per share of €0.12 next year compared to a net loss per share of €0.24 last year.Reported Earnings • Oct 10First half 2025 earnings released: €0.099 loss per share (vs €0.14 loss in 1H 2024)First half 2025 results: €0.099 loss per share (improved from €0.14 loss in 1H 2024). Net loss: €2.43m (loss narrowed 21% from 1H 2024). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Buy Or Sell Opportunity • Sep 30Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 79% to €1.35. The fair value is estimated to be €1.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • Sep 15Now 20% undervaluedOver the last 90 days, the stock has risen 11% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • Aug 22Now 21% undervaluedOver the last 90 days, the stock has risen 6.8% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • Aug 06Now 21% undervaluedOver the last 90 days, the stock has risen 20% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • Jun 16Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.78. The fair value is estimated to be €1.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.Buy Or Sell Opportunity • May 16Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.8% to €0.75. The fair value is estimated to be €1.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (€768k revenue, or US$852k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€3.6m). Currently unprofitable and not forecast to become profitable over next 3 years (€2.3m net loss in 3 years). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€20.5m market cap, or US$22.8m).お知らせ • Apr 15Ulisse Biomed S.p.A., Annual General Meeting, Apr 28, 2025Ulisse Biomed S.p.A., Annual General Meeting, Apr 28, 2025, at 15:00 W. Europe Standard Time.Breakeven Date Change • May 24No longer forecast to breakevenThe analyst covering Ulisse Biomed no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €269.2k in 2024. New forecast suggests the company will make a loss of €530.0k in 2025.Reported Earnings • May 21Full year 2023 earnings releasedFull year 2023 results: Net loss: €4.80m (loss widened 267% from FY 2022). Revenue is forecast to grow 64% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe.New Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$99k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (€27.8m market cap, or US$30.2m).Buy Or Sell Opportunity • May 11Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 25% to €1.17. The fair value is estimated to be €1.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 54% over the last year. Earnings per share has declined by 117%. Revenue is forecast to grow by 866% in a year. Earnings are forecast to grow by 54% in the next year.Buy Or Sell Opportunity • Apr 22Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to €1.23. The fair value is estimated to be €1.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 54% over the last year. Earnings per share has declined by 117%. Revenue is forecast to grow by 866% in a year. Earnings are forecast to grow by 54% in the next year.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$97k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€29.8m market cap, or US$31.6m).New Risk • Jan 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 167% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$99k). Minor Risk Market cap is less than US$100m (€40.6m market cap, or US$44.4m).Buying Opportunity • Sep 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.5%. The fair value is estimated to be €2.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.1% over the last 3 years. Earnings per share has declined by 16%. Revenue is forecast to grow by 575% in a year. Earnings is forecast to grow by 79% in the next year.分析記事 • Jun 24A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)Key Insights Ulisse Biomed's estimated fair value is €1.52 based on 2 Stage Free Cash Flow to Equity Ulisse Biomed's...分析記事 • Feb 17We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Price Target Changed • Nov 16Price target decreased to €1.65Down from €2.15, the current price target is provided by 1 analyst. New target price is 53% above last closing price of €1.08. Stock is down 69% over the past year. The company posted a net loss per share of €0.075 last year.Buying Opportunity • May 31Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €2.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 289% in 2 years. Earnings is forecast to grow by 85% in the next 2 years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €1.85, the stock trades at a trailing P/E ratio of 74.2x. Average forward P/E is 38x in the Biotechs industry in Europe. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Helyx Industries は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BIT:HLX - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-4-2-2N/A9/30/20251-5N/AN/AN/A6/30/20251-5-3-3N/A3/31/20251-6-3-3N/A12/31/20241-6-4-4N/A9/30/20241-6N/AN/AN/A6/30/20240-7-2-2N/A3/31/20240-6-2-1N/A12/31/20230-5-1-1N/A9/30/20230-3N/AN/AN/A6/30/20230-2-2-1N/A3/31/20230-1-1-1N/A12/31/20220-1-1-1N/A9/30/20220-1N/AN/AN/A6/30/20220-1-2-1N/A3/31/20220-1-2-1N/A12/31/20210-1-10N/A9/30/202100N/AN/AN/A6/30/20211001N/A3/31/20211000N/A12/31/202010-1-1N/A12/31/20190-100N/A12/31/20180-2N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: HLXの予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: HLXの収益がItalian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: HLXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: HLXの収益がItalian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: HLXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: HLXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 08:27終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Helyx Industries S.p.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Valentina RomitelliValueTrack
Price Target Changed • Oct 17Price target increased by 18% to €1.16Up from €0.98, the current price target is an average from 2 analysts. New target price is 12% above last closing price of €1.04. Stock is up 8.7% over the past year. The company is forecast to post a net loss per share of €0.12 next year compared to a net loss per share of €0.24 last year.
Breakeven Date Change • May 24No longer forecast to breakevenThe analyst covering Ulisse Biomed no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €269.2k in 2024. New forecast suggests the company will make a loss of €530.0k in 2025.
Price Target Changed • Nov 16Price target decreased to €1.65Down from €2.15, the current price target is provided by 1 analyst. New target price is 53% above last closing price of €1.08. Stock is down 69% over the past year. The company posted a net loss per share of €0.075 last year.
New Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.9m free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Revenue is less than US$5m (€1.9m revenue, or US$2.2m). Market cap is less than US$100m (€15.8m market cap, or US$18.3m).
Reported Earnings • Apr 16Full year 2025 earnings releasedFull year 2025 results: Revenue: €2.23m (up 191% from FY 2024). Net loss: €4.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
New Risk • Apr 15New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 61% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.3m net loss in 2 years). Revenue is less than US$5m (€926k revenue, or US$1.1m). Market cap is less than US$100m (€15.3m market cap, or US$18.0m).
お知らせ • Apr 14Helyx Industries S.p.A., Annual General Meeting, Apr 28, 2026Helyx Industries S.p.A., Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: via montebello n 27, milano Italy
New Risk • Mar 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€2.7m). Currently unprofitable and not forecast to become profitable over next 3 years (€3.0m net loss in 3 years). Share price has been volatile over the past 3 months (7.2% average weekly change). Revenue is less than US$5m (€926k revenue, or US$1.1m). Market cap is less than US$100m (€16.4m market cap, or US$18.9m).
Price Target Changed • Oct 17Price target increased by 18% to €1.16Up from €0.98, the current price target is an average from 2 analysts. New target price is 12% above last closing price of €1.04. Stock is up 8.7% over the past year. The company is forecast to post a net loss per share of €0.12 next year compared to a net loss per share of €0.24 last year.
Reported Earnings • Oct 10First half 2025 earnings released: €0.099 loss per share (vs €0.14 loss in 1H 2024)First half 2025 results: €0.099 loss per share (improved from €0.14 loss in 1H 2024). Net loss: €2.43m (loss narrowed 21% from 1H 2024). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Sep 30Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 79% to €1.35. The fair value is estimated to be €1.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • Sep 15Now 20% undervaluedOver the last 90 days, the stock has risen 11% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • Aug 22Now 21% undervaluedOver the last 90 days, the stock has risen 6.8% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • Aug 06Now 21% undervaluedOver the last 90 days, the stock has risen 20% to €0.88. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • Jun 16Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.78. The fair value is estimated to be €1.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 35%. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
Buy Or Sell Opportunity • May 16Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.8% to €0.75. The fair value is estimated to be €1.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 45% per annum. Earnings are also forecast to grow by 33% per annum over the same time period.
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (€768k revenue, or US$852k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€3.6m). Currently unprofitable and not forecast to become profitable over next 3 years (€2.3m net loss in 3 years). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€20.5m market cap, or US$22.8m).
お知らせ • Apr 15Ulisse Biomed S.p.A., Annual General Meeting, Apr 28, 2025Ulisse Biomed S.p.A., Annual General Meeting, Apr 28, 2025, at 15:00 W. Europe Standard Time.
Breakeven Date Change • May 24No longer forecast to breakevenThe analyst covering Ulisse Biomed no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €269.2k in 2024. New forecast suggests the company will make a loss of €530.0k in 2025.
Reported Earnings • May 21Full year 2023 earnings releasedFull year 2023 results: Net loss: €4.80m (loss widened 267% from FY 2022). Revenue is forecast to grow 64% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe.
New Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$99k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (€27.8m market cap, or US$30.2m).
Buy Or Sell Opportunity • May 11Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 25% to €1.17. The fair value is estimated to be €1.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 54% over the last year. Earnings per share has declined by 117%. Revenue is forecast to grow by 866% in a year. Earnings are forecast to grow by 54% in the next year.
Buy Or Sell Opportunity • Apr 22Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to €1.23. The fair value is estimated to be €1.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 54% over the last year. Earnings per share has declined by 117%. Revenue is forecast to grow by 866% in a year. Earnings are forecast to grow by 54% in the next year.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$97k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€29.8m market cap, or US$31.6m).
New Risk • Jan 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 167% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Shareholders have been substantially diluted in the past year (167% increase in shares outstanding). Revenue is less than US$1m (€91k revenue, or US$99k). Minor Risk Market cap is less than US$100m (€40.6m market cap, or US$44.4m).
Buying Opportunity • Sep 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.5%. The fair value is estimated to be €2.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.1% over the last 3 years. Earnings per share has declined by 16%. Revenue is forecast to grow by 575% in a year. Earnings is forecast to grow by 79% in the next year.
分析記事 • Jun 24A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)Key Insights Ulisse Biomed's estimated fair value is €1.52 based on 2 Stage Free Cash Flow to Equity Ulisse Biomed's...
分析記事 • Feb 17We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Price Target Changed • Nov 16Price target decreased to €1.65Down from €2.15, the current price target is provided by 1 analyst. New target price is 53% above last closing price of €1.08. Stock is down 69% over the past year. The company posted a net loss per share of €0.075 last year.
Buying Opportunity • May 31Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €2.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 289% in 2 years. Earnings is forecast to grow by 85% in the next 2 years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €1.85, the stock trades at a trailing P/E ratio of 74.2x. Average forward P/E is 38x in the Biotechs industry in Europe.